New combo aims to stop leukemia return in older patients

NCT ID NCT07463768

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding ivosidenib to oral azacitidine (Onureg) can help prevent acute myeloid leukemia (AML) from coming back in people over 55 who have a specific IDH1 mutation and are already in remission after chemotherapy. About 60 participants will take both pills daily until the disease returns or side effects become too much. The main goal is to see how many remain relapse-free after two years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CH côte Basque

    Bayonne, 64109, France

  • CH de Perpignan

    Perpignan, 66046, France

  • CHRU Nancy

    Vandœuvre-lès-Nancy, 54500, France

  • CHU Angers

    Angers, 49933, France

  • CHU Besançon

    Besançon, 25030, France

  • CHU Grenoble

    Grenoble, 38043, France

  • CHU Henri Mondor

    Créteil, 94000, France

  • CHU de Limoges

    Limoges, 87000, France

  • CHU de Nantes

    Nantes, 44093, France

  • CHU de Nîmes - Institut de Cancérologie du Gard

    Nîmes, 30029, France

  • CHU de TOULOUSE - IUCT ONCOPOLE

    Toulouse, 31059, France

  • Centre Henri Becquerel

    Rouen, 76038, France

  • Chru Bretonneau

    Tours, 37044, France

  • Chru de Lille - Hopital Claude Huriez

    Lille, 59037, France

  • Chu de Rennes - Hopital Pontchaillou

    Rennes, 35033, France

  • Gustave Roussy

    Villejuif, 94800, France

  • Hopital d'Instruction des Armées Percy

    Clamart, 92140, France

  • Hôpital Haut-Lévêque

    Pessac, 33604, France

  • Hôpital Lyon-Sud

    Pierre-Bénite, 69310, France

  • Hôpital Saint Louis

    Paris, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.